Management of Cerebral Amyloid Angiopathy

Introduction to CAA Management

• Cerebral amyloid angiopathy (CAA) is a condition that increases the risk of lobar hemorrhage with anticoagulants, and falls risk further compounds bleeding risk, especially intracranial hemorrhage, as noted by the American Heart Association/American Stroke Association 1

Patient Assessment and Risk Factors

• A history of lobar ICH suggestive of CAA is a risk factor that appears sufficient to tip the balance away from anticoagulation in nonvalvular AF, according to the American Heart Association/American Stroke Association guidelines 1
• CAA dramatically increases the risk of lobar hemorrhage with anticoagulants, and falls risk further compounds bleeding risk, especially intracranial hemorrhage 1

Antithrombotic Therapy

• The American Heart Association/American Stroke Association recommends avoiding all oral anticoagulants (DOACs and warfarin) due to prohibitively high bleeding risk in patients with CAA 1
• Single antiplatelet therapy with clopidogrel 75mg daily is preferred over aspirin in patients with CAA 2
• Aspirin 75-100mg daily can be continued if already tolerated by the patient with CAA 3

Alternative Stroke Prevention Strategies

• Left atrial appendage occlusion (LAAO) should be considered for patients with atrial fibrillation who need stroke prevention, as it offers a viable alternative to anticoagulation in patients with CAA and high falls risk, recommended by the European Society of Cardiology and the American Heart Association/American Stroke Association 1, 4

Management of Complex Cases

• In patients with recent coronary stenting, minimize duration of dual antiplatelet therapy to the shortest effective period, and consider early cessation of aspirin (≤1 week) and continuation with clopidogrel alone 5
• Avoid triple therapy (dual antiplatelet plus anticoagulant) in patients with CAA and high falls risk 6
• For patients with mechanical heart valve or moderate-severe mitral stenosis, the American Heart Association recommends switching to warfarin with target INR 2.5-3.5 for mechanical mitral valves and target INR 2.0-3.0 for other valvular conditions 7

Key Considerations

• Aggressive blood pressure control reduces ICH risk by up to 77% in CAA patients, and is a crucial consideration in managing patients with CAA
• Fall prevention measures, including physical therapy, home safety evaluation, and assistive devices, are essential in reducing the risk of intracranial hemorrhage in patients with CAA
• Direct oral anticoagulants (DOACs) and other blood thinners are contraindicated in patients with a recent history of hemorrhagic stroke, and should be used with extreme caution in those with a remote history of hemorrhagic stroke due to the significantly increased risk of recurrent bleeding, as recommended by the American Heart Association 7
• The time since hemorrhage is crucial, with recent hemorrhage (<4-8 weeks) being an absolute contraindication and remote hemorrhage (>4-8 weeks) being a relative contraindication that requires careful risk-benefit assessment, as supported by 7
• Regular monitoring including neurological assessments, blood pressure control, periodic imaging surveillance, and regular assessment of renal function for patients on DOACs is crucial, as recommended by the American College of Chest Physicians and the European Heart Society 7, 4
• Medication adherence should be evaluated at each visit, as supported by 8
• The decision to restart antithrombotic therapy after ICH depends on the risk of subsequent arterial or venous thromboembolism, the risk of recurrent ICH, and the overall status of the patient, as recommended by the Stroke journal and the American Heart Association/American Stroke Association 9, 7

Lifestyle Modifications

• Regular physical activity (150-300 minutes of moderate intensity exercise per week) is recommended, along with avoidance of excessive alcohol consumption, aggressive management of hypertension, diabetes, and hyperlipidemia, smoking cessation, and weight reduction in obese individuals, as supported by 4

Follow-up and Monitoring

• Regular clinical assessment for new neurological symptoms is necessary, along with periodic imaging surveillance (MRI or CT) to detect new silent infarcts, laboratory monitoring for patients switched to warfarin (INR testing) with a target range of 2.0-3.0, and regular assessment of renal function for patients on DOACs, as recommended by the American College of Chest Physicians and the European Heart Society 8, 10, 7, 4